ASAQ Sanofi-Aventis

by

QUESTION

In the summer of 2010 I went to Uganda on a medical trip where we saw hundreds of people affected by malaria. Ever since, I have had a huge heart for these children that we saw at the orphanage. This past summer, I took a Microbiology class at the University of Tennessee where we learned about Sanofi-Aventis and the affordable malaria medication made in 2007. I am starting an annual 5k in honor of my father who passed away to raise money to buy this medication to give to children in Uganda (my church has a medical clinic over there). I was wondering how I would go about obtaining this medication or if you could help me in any way. Thank you so much for your time.

ANSWER

It’s great that you have become passionate about helping people fight malaria in Uganda. In terms of helping people with access to anti-malarial medicine, I can think of three ways you could go about it.

First of all, you could raise money to donate to an organization which already works on health issues in the area of Uganda in which your church operates. You would need to do some research on what organizations operate in the area, and also try to find out a bit about their reputation and overheads (it’s frustrating to see your donations whittled away on mundane, if important, bureaucratic costs rather than going directly into buying medication). Alternatively, but along the same lines, you could look into donating the money directly to the medical clinic that your church supports, and see if they can purchase the necessary medications locally or at least within Uganda. Both of these approaches have the advantage that you will be partnering with people who already work in the area, know the local landscape, and have relationships with local government health clinics and other local authorities, who may hear of your action and feel the need to be informed. The disadvantage is that you would be reliant on drug supplies available in the area; throughout Africa, there are recurrent problems of people buying counterfeit drugs, or being given expired pills.

Similarly, supplies are not always reliable, and you might have to settle for buying whatever drug is available, regardless of the formulation or brand (though I would strongly encourage you to ONLY buy artemisinin-based combination therapies, or ACTs, of which Coarsucam and ASAQ Winthrop, both fixed dose combinations of artesunate-amodiaquine created by Sanofi-Aventis, are included).

Your third option, which is probably the most logistically challenging but over which you would have the most control, would be to solicit pharmaceutical companies directly to see if they would be willing to sell you pills directly at whole sale price, based on the money you raise from your annual race. Many pharmaceutical companies already have programs to develop health care initiatives and improve public health in the world’s poorest companies, so you could try to include your project as one of these initiatives.

Sanofi-Aventis itself has a program called Impact Malaria which works with a variety of stakeholders to tackle malaria on the ground, and which includes distribution of the drugs mentioned above. You could also look into other pharmaceutical companies that develop anti-malarial drugs, such as Novartis (which produces Coartem), Lonart (Bliss Gvs Pharma), and many others. One thing to bear in mind is that there are often restrictions on importing and exporting drugs, and also many other things to consider when doing drug donations.

This paper outlines some of the issues you should be thinking about if you want to go down the direct donation path: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121783/

The Institute for OneWorld Health Announces Development of Alternative Source of Artemisinin

by

The Institute for OneWorld Health (iOWH), a non-profit drug development organization, announced today that its development of an alternative source of artemisinin using pioneering synthetic biology technology (semisynthetic artemisinin (ART) project) has successfully entered the production and distribution phase.

The semisynthetic version of artemisinin is targeted to be an affordable, non-seasonal and complementary source of ART and will stabilize price volatility and alleviate shortages – key factors in meeting future demand in developing nations and around the globe.

iOWH, in collaboration with its strategic partners, successfully completed the scientific work necessary to enter the production and distribution phase of the project. Through a unique public-private partnership with sanofi-aventis, a leading global pharmaceutical company, this phase will enable production of semisynthetic ART. Sanofi has made essential contributions during the project’s development and industrialization phase, and is going to manufacture and distribute the semi synthetic artemisinin version to any qualified buyer. The substantial investment sanofi-aventis is making in this project will make it possible to facilitate integration of semisynthetic ART into the ACTs and the global supply chain, with an estimated goal to begin distribution in 2012.

“When we started work on this project, nearly six years ago, we knew that this would be a major challenge from technical, scientific, and humanitarian standpoints. Here we are today; however, ready to begin the production and distribution phase in collaboration with sanofi, thanks to the hard work of our team, our collaborators, and our subgrantees, as well as generous support from our funders. Our goal is that one day; no child will die from malaria. Providing an alternative source of artemisinin is a breakthrough in the fight against malaria,” said Richard Chin, M.D., CEO of iOWH.

“Realizing this project brings us enormous satisfaction that only our profession, devoted to public health and patient care, can offer. Contributing to a project which saves lives and relieves suffering within the context of a fair trade economic model, combined with technological challenges and partnership, is a source of inspiration for all members of our team,” said Francis Carré, CEO of Sanofi Chimie.

iOWH has led this project, funded by the Bill & Melinda Gates Foundation, in collaboration with Amyris Inc. and sanofi-aventis. The synthetic biology technology is based on pioneering inventions licensed from the University of California at Berkeley and the University of Saskatchewan. Headquartered in South San Francisco, iOWH is a non-profit that discovers, develops and delivers safe, effective and affordable new medicines for vulnerable population with infectious diseases in the developing world, with emphasis on diseases that disproportionately affect children.

Source: Business Wire

Canadian Researchers Develop Inexpensive Malaria Treatment

by

Scientists in Saskatoon, Canada have developed a malaria treatment that will help fight malaria, which kills about one million people each year.

The new developments which will provide an affordable, reliable, and stable treatment for malaria and is likely to save millions of lives, especially those of women and children in Africa. The Honourable Gary Goodyear, Minister of State for Science and Technology, along with Mr. Brad Trost, Member of Parliament for Saskatoon–Humboldt, announced the breakthrough today and highlighted the Government’s research support.

“Our government is committed to improving the health of women and children in developing countries,” said Minister Goodyear. “This new development in the production of a malaria treatment represents a major development in the fight against the disease. It will strengthen Canada’s position as a world leader in health research and provide a reliable and affordable solution.”

Today’s announcement is a result of  The Artemisinin Project, a public-private partnership led by OneWorld Health in collaboration with sanofi-aventis, Amyris, the University of California at Berkeley, and the National Research Council Canada. Artemisinin is a natural compound found in a traditional Chinese medicinal plant grown mainly in Africa and Asia to treat malaria. The Government of Canada’s investment of approximately $869,000 in this research has led to technology that can produce a stable and affordable supply of artemisinin for the developing world on a not-for-profit basis.

“Collaboration on the development of this new technology promises to have a major impact on supply of malaria treatment across the developing world, which will be an important contribution towards the global effort to combat malaria,” said Dr. Richard Chin, Chief Executive Officer of OneWorld Health.

According to the World Health Organization, malaria causes approximately 250 million illnesses and more than one million deaths each year, of which 90 percent occur in Africa, mostly in pregnant women and in children. The disease is endemic in nearly 100 countries, including 28 on the African continent. This project is expected to help treat 200 million cases and prevent over one million deaths annually.

About the National Research Council of Canada’s Artemisinin Research

In 2003, researchers at the National Research Council of Canada (NRC) in Saskatoon set out to identify the genes that control the synthesis of artemisinin. Produced by Artemisia annua (a traditional Chinese medicinal plant), this natural compound is extracted from plants grown in Africa and Asia to treat malaria — a major threat to maternal and child health around the world.

Led by Dr. Patrick Covello, the NRC team identified various genes in the plant’s metabolic pathway that produce artemisinin. Using various microbial and plant platforms, such as yeast and tobacco, they conducted research to find alternative means of supplying low cost artemisinin-based drugs.

The Government of Canada has invested approximately $869,000 in this research. In partnership with Amyris, OneWorld Health and sanofi-aventis, NRC’s technology promises to have a major impact on malaria treatment across the developing world.

The NRC worked in partnership with “The Artemisinin Project,” funded by the Bill & Melinda Gates Foundation. This project is led by OneWorld Health, in collaboration with Amyris Biotechnologies, the University of California at Berkeley, and sanofi-aventis.

In 2004, the Institute for OneWorld Health was awarded $42.6 million from the Bill & Melinda Gates Foundation to develop a new source of artemisinin for distribution to the developing world. OneWorld Health created a collaboration between researchers at the University of California, Berkeley who were using yeast to synthesize high-value natural compounds produced by higher plants and other organisms. This work led to the creation of Amyris, a spin-off company, who also joined the collaboration. The aim of the Artemisinin Project was to identify genes in the artemisinin pathway and develop yeast strains that could produce large amounts of artemisinic acid, a key intermediate for the synthesis of artemisinin.

In 2008, the NRC and Amyris signed a license agreement, allowing the company to incorporate NRC’s discovery of two key genes in the artemisinin pathway into Amyris’ proprietary system, effectively doubling the yield of the end-product.

Subsequent to these research milestones, in July 2010, OneWorld Health announced an additional grant of $10.7 million from the Bill & Melinda Gates Foundation to scale-up production and commercialize the drug. Global pharmaceutical company, sanofi-aventis, is the partner that will formulate the drug for distribution on a not-for-profit basis across Africa and other regions vulnerable to the disease.

About Malaria

Malaria is a life-threatening parasitic disease transmitted by infected mosquitoes. Its symptoms include extreme exhaustion, fits of high fever, sweating, shaking chills and anemia.

Malaria parasites destroy red blood cells in the body, leading to anemia. Without adequate treatment, infected red blood cells block vessels leading to the brain or damage other vital organs, often resulting in death.

Infected people living in highly endemic areas often develop immunity to the disease and become asymptomatic carriers of malaria, contributing to epidemics.

According to the World Health Organization, malaria causes approximately 250 million illnesses and more than one million deaths per year, of which 90 percent occur in Sub-Saharan Africa. Malaria is endemic in nearly 100 countries, including 28 countries on the African continent.

In many countries, malaria is the leading killer of children under 5 years of age. Many children who survive an episode of severe malaria suffer learning impairments or brain damage.

Pregnant women and their unborn children are particularly vulnerable to malaria. More than 45 million women — 30 million in Africa — become pregnant in malaria-endemic areas each year.

During pregnancy, malaria can cause maternal anemia, impaired fetal growth, spontaneous abortion, stillbirth, premature birth and low birth weight. In sub-Saharan Africa, up to 40 percent of low birth weight is due to maternal malaria, resulting in up to 400,000 infant deaths per year.

In many areas, the malaria parasite is increasingly resistant to older, inexpensive, single drugs such as chloroquine. Currently, the most effective treatments involve combinations of artemisinin-based therapies and other antimalarials to prolong each drug’s effectiveness and delay resistance.

The source of artemisinin — Artemisia annua (also known as wormwood) — is cultivated mainly in Africa and Asia. However, because of the agricultural time scale, the delay between increased demand and new supply can be up to 14 months, causing shortages and limiting the ability to control the disease.

Source: National Research Council Canada